What dose of vitamin K (phylloquinone) should be administered to a patient with a history of cerebral infarction, currently on warfarin (coumarin), with an elevated International Normalized Ratio (INR) and no observed bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vitamin K Dosing for Elevated INR Without Bleeding in Post-Stroke Warfarin Patient

Direct Recommendation

For a patient with cerebral infarction history on warfarin with elevated INR and no bleeding, withhold warfarin for 1-2 doses and monitor serial INR determinations without administering vitamin K if the INR is between 4.5-10. 1, 2

Evidence-Based Management Algorithm

INR 4.5-10 Without Bleeding (Most Likely Scenario)

  • The American College of Chest Physicians explicitly recommends AGAINST routine vitamin K use for INR 4.5-10 without bleeding (Grade 2B recommendation), as randomized trials demonstrate no reduction in major bleeding rates despite faster INR normalization 1

  • Pooled analysis of four RCTs showed similar major bleeding rates over 1-3 months: 2% (10/452) with vitamin K versus 0.8% (4/471) with placebo alone 1

  • Simply withhold warfarin and monitor INR every 24-48 hours until it returns to therapeutic range 1, 2

  • Add oral vitamin K 1-2.5 mg ONLY if the patient has high bleeding risk factors including advanced age (>65-75 years), history of prior bleeding, concomitant antiplatelet drugs, renal failure, or alcohol use 1, 3, 2

INR >10 Without Bleeding

  • Administer oral vitamin K 5 mg immediately in addition to withholding warfarin 3, 4

  • A prospective cohort study of 107 patients with INR >10 treated with 2.5 mg oral vitamin K showed only 3.9% major bleeding rate at 90 days 1, 5

  • Recheck INR within 24 hours to confirm appropriate reduction 3, 2

Critical Considerations for Stroke Patients

  • Patients with cerebral infarction history require particularly careful balancing of bleeding versus thromboembolism risk 1

  • The risk of thromboembolism with overcorrection appears similar to bleeding risk from over-anticoagulation 6

  • Avoid high-dose vitamin K (≥10 mg) in non-bleeding scenarios, as this creates warfarin resistance for up to a week and makes re-anticoagulation extremely difficult 3, 2

Route of Administration

  • Oral vitamin K is strongly preferred for all non-bleeding scenarios due to predictable effectiveness (95% of patients show INR reduction within 24 hours), convenience, and safety 3, 2, 6

  • Intravenous vitamin K should be reserved ONLY for active major bleeding, administered by slow infusion over 30 minutes due to anaphylactoid reaction risk (3 per 100,000 doses) 3, 4

  • Subcutaneous route is less effective and associated with cutaneous reactions 6

Common Pitfalls to Avoid

  • Do not administer vitamin K reflexively for every elevated INR - the evidence shows no benefit for patient-important outcomes (bleeding, thromboembolism, mortality) when INR is 4.5-10 without bleeding 1

  • Never use high doses unnecessarily - doses >10 mg create a prothrombotic state and prevent re-warfarinization for days 3

  • Do not forget to investigate the cause of INR elevation before resuming warfarin - look for drug interactions, dietary changes in vitamin K intake, intercurrent illness, medication non-adherence, or alcohol consumption 2

  • When resuming warfarin, reduce the weekly dose by 10-20% to prevent recurrence of supratherapeutic INR 2

Monitoring Strategy

  • Recheck INR within 24-48 hours after any intervention to confirm appropriate reduction 3, 2

  • Continue monitoring every 24-48 hours until INR stabilizes in therapeutic range 3

  • After oral vitamin K administration, 85% of patients achieve INR <4.0 within 24 hours 3, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Elevated INR on Warfarin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Warfarin Reversal in Significant Bleeding or Emergency Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The use of vitamin K in patients on anticoagulant therapy: a practical guide.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004

Related Questions

What is the management for a patient with a supratherapeutic International Normalized Ratio (INR) using vitamin K?
What is the point of giving 10mg of vitamin K to a patient with a rising International Normalized Ratio (INR) off warfarin (coumarin) and suspected liver failure, as the liver may struggle to utilize it for clotting factor production?
How is an elevated International Normalized Ratio (INR) of 3.5 best corrected in patients taking warfarin (Coumadin)?
What is the recommended dosing of vitamin K (Vitamin K) for an adult patient with a history of anaphylaxis and elevated International Normalized Ratio (INR) who is on anticoagulant therapy?
At what International Normalized Ratio (INR) level is vitamin K administered?
What is the recommended management for a patient with chicken pox, including treatment options for fever, itching, and high-risk complications?
What is the treatment approach for a patient with cirrhosis (scarring of the liver) without complications, stable medical history, and no significant comorbidities?
What is the next step for an adult patient with a history of cerebral infarction, currently receiving coumadin (warfarin) 5mg daily, with an elevated International Normalized Ratio (INR) of 5.6 and no observed bleeding?
Why would a patient with leukocytosis and thrombocytosis be given D5NS (5% dextrose in normal saline)?
Why is D5NS (5% dextrose in normal saline) given to a pediatric patient with leukocytosis and thrombocytosis, likely due to a hematologic malignancy?
What are the potential causes of dark brown and foamy urine in a patient with a possible history of kidney stones, urinary tract infections, or other renal conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.